Klotho Neurosciences (NASDAQ:KLTO) vs. ImmunityBio (NASDAQ:IBRX) Head-To-Head Comparison

Klotho Neurosciences (NASDAQ:KLTO) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Profitability

This table compares Klotho Neurosciences and ImmunityBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Klotho Neurosciences	N/A	-1.48%	-25.89%
ImmunityBio	-8,016.83%	N/A	-110.02%

Earnings & Valuation

This table compares Klotho Neurosciences and ImmunityBio”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Klotho Neurosciences	N/A	N/A	$1.35 million	N/A	N/A
ImmunityBio	$7.33 million	249.95	-$583.20 million	($0.92)	-2.86

Klotho Neurosciences has higher earnings, but lower revenue than ImmunityBio.

Institutional & Insider Ownership

20.1% of Klotho Neurosciences shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 2.0% of Klotho Neurosciences shares are held by company insiders. Comparatively, 83.4% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for Klotho Neurosciences and ImmunityBio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Klotho Neurosciences	0	0	0	0	0.00
ImmunityBio	0	1	1	1	3.00

ImmunityBio has a consensus price target of $17.38, indicating a potential upside of 560.65%. Given ImmunityBio’s stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Klotho Neurosciences.

Summary

ImmunityBio beats Klotho Neurosciences on 7 of the 11 factors compared between the two stocks.

About Klotho Neurosciences

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

About ImmunityBio

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.